{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Naidoo J"],"funding":["National Cancer Institute","NCI NIH HHS","Merck Sharp and Dohme"],"pagination":["e002473"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8359453"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(8)"],"pubmed_abstract":["<h4>Background</h4>The benefit of immune checkpoint inhibitors (ICIs) in patients with leptomeningeal metastases (LMM) is unknown.<h4>Methods</h4>We undertook a phase II trial of pembrolizumab in patients with LMM from solid tumors. Eligible patients had radiologic/cytologic LMM and Eastern Cooperative Oncology Group performance status 0-1. Pembrolizumab was administered intravenously at 200 mg q3W until disease progression/unacceptable toxicity. The primary endpoint was central nervous system (CNS) response after four cycles, defined radiologically/cytologically/clinically. Serial cerebrospinal fluid (CSF) was assessed for tumor-derived DNA (t-DNA) aneuploidy and cytokines.<h4>Results</h4>Thirteen of a planned 16 patients were treated between April 2017 and December 2019. The study closed"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers."],"pmcid":["PMC8359453"],"funding_grant_id":["U01 CA230691","NIH RA37CA230400","U01CA230691","R37 CA230400"],"pubmed_authors":["Papadopoulos N","Schreck KC","Connolly RM","Riemer J","Naidoo J","Carvajal-Gonzalez A","Bettegowda C","Douville C","Kinzler KW","Brahmer JR","Fu W","Aygun N","Kleinberg L","Venkatesan A","Forde PM","Hu C","Grossman SA","Lipson EJ","Holdhoff M","Santa-Maria CA","Barnes A","Page B","Redmond KJ"],"additional_accession":[]},"is_claimable":false,"name":"Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers.","description":"<h4>Background</h4>The benefit of immune checkpoint inhibitors (ICIs) in patients with leptomeningeal metastases (LMM) is unknown.<h4>Methods</h4>We undertook a phase II trial of pembrolizumab in patients with LMM from solid tumors. Eligible patients had radiologic/cytologic LMM and Eastern Cooperative Oncology Group performance status 0-1. Pembrolizumab was administered intravenously at 200 mg q3W until disease progression/unacceptable toxicity. The primary endpoint was central nervous system (CNS) response after four cycles, defined radiologically/cytologically/clinically. Serial cerebrospinal fluid (CSF) was assessed for tumor-derived DNA (t-DNA) aneuploidy and cytokines.<h4>Results</h4>Thirteen of a planned 16 patients were treated between April 2017 and December 2019. The study closed","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Aug","modification":"2026-06-16T03:11:56.224Z","creation":"2026-06-16T03:07:04.065Z"},"accession":"S-EPMC8359453","cross_references":{"pubmed":["34380662"],"doi":["10.1136/jitc-2021-002473"]}}